A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin

References

• International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017
   Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26:77-82
   Google Scholar
• Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2018. Diabetes Care 2018;41(Suppl 1):S1-S159
   PubMedGoogle Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 executive summary. Endocr Pract 2018;24:91-120
   PubMed Web of Science ®Google Scholar
• Laiteerapong N, Fairchild PC, Chou CH, et al. Revisiting disparities in quality of care among US adults with diabetes in the era of individualized care, NHANES 2007–2010. Med Care 2015;53:25-31
   PubMed Web of Science ®Google Scholar
• Bailey RA, Damaraju CV, Martin SC, et al. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. Am J Manag Care 2014;20(1 Suppl):S16-S24
   PubMed Web of Science ®Google Scholar
• Fallon Health. 2018 HEDIS measures. 2017. Available at: http://www.fchp.org/providers/resources/hedis-measures.aspx [Last accessed 3 January 2018]
   Google Scholar
• Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 2013;368:1613-24
   PubMed Web of Science ®Google Scholar
• Carls G, Huynh J, Tuttle E, et al. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther 2017;8:863-73
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, Bellows BK, Unni S, et al. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. J Manag Care Pharm 2014;20:691-700
   PubMed Web of Science ®Google Scholar
• Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 2012;35:1279-84
   PubMed Web of Science ®Google Scholar
• Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41
   PubMed Web of Science ®Google Scholar
• Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-5
   PubMed Web of Science ®Google Scholar
• Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 2014;66:255-70
   PubMed Web of Science ®Google Scholar
• AstraZeneca. US FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes. Available at: https://www.astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-farxiga-treatment-type-2-diabetes-patients-13012014.html# [Last accessed 4 January 2018]
   Google Scholar
• Johnson & Johnson. U.S. FDA approves INVOKANA™ (canagliflozin) for the treatment of adults with type 2 diabetes. 2013. Available at: https://www.jnj.com/media-center/press-releases/us-fda-approves-invokana-canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes [Last accessed 4 January 2018]
   Google Scholar
• INVOKANA^® (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals, 2017
   Google Scholar
• FARXIGA^® (dapagliflozin) tablets, for oral use [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2015
   Google Scholar
• Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann NY Acad Sci 2015;1358:28-43
   PubMed Web of Science ®Google Scholar
• Anderson SL. Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf 2014;5:242-54
   PubMedGoogle Scholar
• Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab 2015;17:188-97
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61
   PubMed Web of Science ®Google Scholar
• Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016;18:783-94
   PubMed Web of Science ®Google Scholar
• Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One 2015;10:e0125879
   PubMed Web of Science ®Google Scholar
• Taieb V, Pacou M, Schroeder M, et al. Bayesian network meta-analysis (NMA) to assess the relative efficacy of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with insulin. Value Health 2015;18:A598
   Web of Science ®Google Scholar
• Taieb V, Pacou M, Schroeder M, et al. A network meta-analysis (NMA) to assess the longer-term relative efficacy of canagliflozin in patients with type 2 diabetes inadequately controlled on metformin. Value Health 2015;18:A598
   Web of Science ®Google Scholar
• Johnston R, Uthman O, Cummins E, et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2017;21:1-218
   PubMed Web of Science ®Google Scholar
• Whittington C, Schubert A, Neslusan C. An assessment of the relative efficacy of sodium glucose co-transporter 2 inhibitors as add-on to metformin in patients with type 2 diabetes mellitus. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress, Vienna, Austria, 29 October–2 November 2016
   Google Scholar
• Candrilli SD, Meyers JL, Boye K, et al. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities. J Diabetes Complications 2015;29:529-33
   PubMed Web of Science ®Google Scholar
• Barner JC. Medication adherence: focus on secondary database analysis. ISPOR student forum presentation: 24 February 2010
   Google Scholar
• Cai J, Wang Y, Baser O, et al. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States. J Med Econ 2016;19:1175-86
   PubMed Web of Science ®Google Scholar
• Cai J, Divino V, Burudpakdee C. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, DPP-4s, or GLP-1s in the United States. Curr Med Res Opin 2017;33:1317-28
   PubMed Web of Science ®Google Scholar
• Buysman EK, Chow W, Henk HJ, et al. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. BMC Endocr Disord 2015;15:67
   PubMed Web of Science ®Google Scholar